Forte Biosciences, Inc. clinical trials
Acquired by argenx, Aug 27, 2026 · source ↗
The registry lists 6 studies whose lead sponsor is Forte Biosciences, Inc.. 4 are recruiting or about to start. Per ClinicalTrials.gov, last updated Oct 21, 2026.
Before and after it joined argenx
- First submitted before Forte Biosciences, Inc. became part of argenx
- 6
- First submitted after Forte Biosciences, Inc. became part of argenx
- 0
- Unclear, or no submission date
- 0
By the date each study was first submitted to the registry. The registry lists today's sponsor name and keeps no history, so this says when a study was filed, not who filed it.
Registry sponsor names on this page
- Forte Biosciences, Inc.6 studies
Something wrong with this grouping? Tell us on the argenx page.
Studies
Recruiting first, then most recently updated. Showing 6 of 6. All argenx studies →
- A Study Testing the Safety and Effects of FB102 in Healthy VolunteersRecruitingNCT07623057Phase 1
Sponsor listed in the registry: Forte Biosciences, Inc. · First submitted before Forte Biosciences, Inc. became part of argenx
- A Study to Evaluate the Safety and Efficacy of FB102 in Patients With Non-segmental VitiligoRecruitingNCT06905873Phase 1
Sponsor listed in the registry: Forte Biosciences, Inc. · First submitted before Forte Biosciences, Inc. became part of argenx
- A Study to Evaluate the Safety and Efficacy of FB102 in Patients With Severe to Very Severe Alopecia Areata.RecruitingNCT07205159Phase 1
Sponsor listed in the registry: Forte Biosciences, Inc. · First submitted before Forte Biosciences, Inc. became part of argenx
- Randomized, Double Blind, Placebo-controlled Phase 2 Study in Adults With Celiac DiseaseRecruitingNCT06982963Phase 2
Sponsor listed in the registry: Forte Biosciences, Inc. · First submitted before Forte Biosciences, Inc. became part of argenx
- Continued Safety Evaluation of FB-401 in Children, Adolescents and Adults (2 Years and Older) With Mild to Moderate Atopic Dermatitis Previously Enrolled in the FB401-01 StudyTerminatedNCT04936113Phase 2
Sponsor listed in the registry: Forte Biosciences, Inc. · First submitted before Forte Biosciences, Inc. became part of argenx
- Evaluation of FB-401 in Children, Adolescents and Adults (2 Years and Older) With Mild to Moderate Atopic DermatitisCompletedNCT04504279Phase 2
Sponsor listed in the registry: Forte Biosciences, Inc. · First submitted before Forte Biosciences, Inc. became part of argenx